Observation in effect of loop electrosurgical excision procedure combined with recombinant human interferon α2b vaginal effervescent capsules in the treatment of cervical intraepithelial neoplasia

  Objective   To observe the clinical efficacy of loop electrosurgical excision procedure (LEEP) combined with recombinant human interferon α2b vaginal effervescent capsules in the treatment of cervical intraepithelial neoplasia (CIN).

  Methods   A total of 186 patients with CIN were selected as study objects, and were randomly divided into study group(n=93) and control group (n=93) according to random number table method. The control group was treated with LEEP, and the study group was treated with recombinant human interferon α2b vaginal effervescent capsules on the basis of the control group. The changes of immune function and operation indexes were observed before and after treatment, and the treatment effect, recurrence rate and complications were compared between the two groups.

  Results   The vaginal discharge volume of patients with CIN Ⅰ, Ⅱ and Ⅲ grade in the study group was less than that in the control group, and the wound healing time patients with CIN Ⅰ was shorter than that in the control group (P <0.05). Compared with the control group, the vaginal discharge volume of patients in the study group was less than that in the control group, vaginal discharge time and wound healing time of the study group were shorter than those in the control group (P <0.05). The levels of CD4⁺, CD4⁺/CD8⁺ in the study group after treatment were higher than those in the control group, and the level of CD8⁺ in the study group was lower than that in the control group (P <0.05). Compared with the control group, the levels of C-reactive protein (CRP) and tumor necrosis factor-α(TNF-α) in the study group were lower, and the level of IL-10 was higher (P <0.05). The total effective rate of the study group was significantly higher than that of the control group (93.55% versus 79.57%, P <0.05), and the postoperative recurrence rate was significantly lower than that of thecontrol group (2.15% versus 13.98%, P <0.05). There was no significant difference in the total incidence of perioperative complications between the two groups (P >0.05).

  Conclusion   LEEP combined with recombinant human interferon α2b vaginal effervescent capsules in the treatment of CIN can effectively regulate the immune function, improve the clinical efficacy and reduce the risk of postoperative recurrence.